Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benchmarking DNA barcode decoding strategies under high error rates.

BMC bioinformatics·2026
Same author

Eosinophilic Pleural Effusion Following Long-Term Asthma Remission Under Dupilumab Therapy: A Search for Clues Using Cytokine Analyses.

Journal of investigational allergology & clinical immunology·2026
Same author

Prolyl-3-hydroxylase 1 is a central regulator of collagen post-translational modifications and the collagen biosynthetic network.

The Journal of biological chemistry·2026
Same author

Pulmonary Hypertension Associated With Interstitial Lung Disease: State-of-the-Art Review.

The European respiratory journal·2026
Same author

Lower Limit of Normal of Pulmonary Function to Define Baseline Lung Allograft Dysfunction.

Transplantation direct·2026
Same author

Sex Differences in IPF: Data from the German INSIGHTS Registry.

Respiration; international review of thoracic diseases·2026
Same journal

Isoleucyl-tRNA synthetase 1 mutation impairs pulmonary surfactant homeostasis by disrupting alveolar macrophage function.

Respiratory research·2026
Same journal

From force to fate: Implications of mechanomemory in lung disease.

Respiratory research·2026
Same journal

Necroptosis in alveolar epithelium orchestrates lung ischemia-reperfusion injury: a multi-omics study.

Respiratory research·2026
Same journal

Integrated phenotyping identifies reproducible prognostic subgroups in idiopathic pleuroparenchymal fibroelastosis.

Respiratory research·2026
Same journal

Bronchovascular texture pattern on quantitative CT reveals airway and vascular remodeling in post-COVID-19 Lungs.

Respiratory research·2026
Same journal

Fibroblast activity biomarkers are associated with mortality in severe COVID-19: a post-hoc analysis of a phase 2 clinical trial.

Respiratory research·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Recommendations on treatment for IPF.

Jürgen Behr1, Luca Richeldi

  • 1Department of Internal Medicine V, University of Munich, Comprehensive Pneumology Center, Marchioninistr, 15, 81377 Munich, Germany. Juergen.Behr@bergmannsheil.de

Respiratory Research
|June 6, 2013
PubMed
Summary
This summary is machine-generated.

Idiopathic Pulmonary Fibrosis (IPF) management guidelines have been updated. Clinicians must interpret these recommendations, considering new drug data and individual patient needs for optimal care.

Related Experiment Videos

Last Updated: May 10, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Area of Science:

  • Pulmonology
  • Clinical Practice Guidelines
  • Idiopathic Pulmonary Fibrosis (IPF)

Background:

  • Idiopathic Pulmonary Fibrosis (IPF) patient management relies on established guidelines.
  • Recent updates from major thoracic societies (ATS, ERS, JRS, ALAT) offer revised guidance.

Purpose of the Study:

  • To interpret recent IPF guideline updates.
  • To discuss implications for clinical practice and pharmacologic approaches.

Main Methods:

  • Review of updated societal guidelines for IPF diagnosis and management.
  • Assessment of pharmacological agents based on clinical trial data and GRADE criteria.

Main Results:

  • No single agent was universally recommended by the guideline committee.
  • Pirfenidone has since been approved in Europe.
  • Negative findings on triple therapy (prednisone, azathioprine, N-acetylcysteine) question its continued use.

Conclusions:

  • Clinicians must critically interpret guidelines alongside emerging data.
  • Individual patient assessment, preferences, and current evidence are crucial for IPF management decisions.